Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study

Autor: Callizo, Josep, Ziemssen, Focke, Bertelmann, Thomas, Feltgen, Nicolas, Vögeler, Jessica, Koch, Mirja, Eter, Nicole, Liakopoulos, Sandra, Schmitz-Valckenberg, Steffen, Spital, Georg
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Zdroj: Clinical Ophthalmology (Auckland, N.Z.)
ISSN: 1177-5483
1177-5467
4955-1396
Popis: Josep Callizo,1 Focke Ziemssen,2 Thomas Bertelmann,3 Nicolas Feltgen,3 Jessica Vögeler,4 Mirja Koch,4 Nicole Eter,5 Sandra Liakopoulos,6 Steffen Schmitz-Valckenberg,7 Georg Spital8 1Department of Ophthalmology, Georg-August University, Goettingen, Germany; 2Center for Ophthalmology, Eberhard Karl University of Tuebingen, Tuebingen, Germany; 3Georg-August-University Goettingen, University Eye Hospital, Goettingen, Germany; 4Novartis Pharma GmbH, Clinical Research, Nuremberg, Germany; 5Department of Ophthalmology, University of Muenster Medical Center, Muenster, Germany; 6Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany; 7Department of Ophthalmology, University of Bonn, Bonn, Germany; 8Augenzentrum Am St. Franziskus Hospital, Muenster, GermanyCorrespondence: Josep CallizoDepartment of Ophthalmology, Georg-August University, Robert-Koch-Str. 40, Goettingen 37075, GermanyTel +495513966776Fax +495513966787Email josep.callizo@med.uni-goettingen.dePurpose: The non-interventional OCEAN study (NCT02194803) evaluated frequency and monitoring of ranibizumab injections for retinal vein occlusion (RVO) in routine practice in Germany.Methods: RVO patients (including branch and central RVO (BRVO/CRVO)) receiving ranibizumab were included. Best-corrected visual acuity (BCVA) testing, imaging and treatment were performed at the investigators’ discretion and documented over 24 months.Results: Overall, 744 RVO patients (27% BRVO, 16% CRVO, remaining unspecified RVO) were included. For 74% of patients, data were available for the 12-month visit and for 56% for the 24-month visit. Mean baseline BCVA was 52.0 Early Treatment for Diabetic Retinopathy Study (ETDRS) letters (BRVO: 55.9, CRVO: 43.9). BCVA improved rapidly within the first 3 months, reaching 64.3 letters at 12 months and 64.7 at 24 months. CRVO patients showed less improvement than those with BRVO. Patients received a median of 4 (5) injections over 12 (24) months, with 100% of patients receiving injections at baseline, 70% at Month 1 and 81% at Month 2. Overall, 40% of patients demonstrated a ≥15 letter increase within the first 3 months (42% BRVO, 46% CRVO). Patients with low initial BCVA (
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje